JP2023089245A5 - - Google Patents

Download PDF

Info

Publication number
JP2023089245A5
JP2023089245A5 JP2023069335A JP2023069335A JP2023089245A5 JP 2023089245 A5 JP2023089245 A5 JP 2023089245A5 JP 2023069335 A JP2023069335 A JP 2023069335A JP 2023069335 A JP2023069335 A JP 2023069335A JP 2023089245 A5 JP2023089245 A5 JP 2023089245A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023069335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023089245A (ja
JP7629651B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/043908 external-priority patent/WO2019023460A1/en
Application filed filed Critical
Publication of JP2023089245A publication Critical patent/JP2023089245A/ja
Publication of JP2023089245A5 publication Critical patent/JP2023089245A5/ja
Priority to JP2025011548A priority Critical patent/JP2025066140A/ja
Application granted granted Critical
Publication of JP7629651B2 publication Critical patent/JP7629651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023069335A 2017-07-27 2023-04-20 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 Active JP7629651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025011548A JP2025066140A (ja) 2017-07-27 2025-01-27 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762537914P 2017-07-27 2017-07-27
US62/537,914 2017-07-27
PCT/US2018/043908 WO2019023460A1 (en) 2017-07-27 2018-07-26 ANTIBODIES AGAINST M (H) DM2 / 4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER
JP2020527850A JP2020528936A (ja) 2017-07-27 2018-07-26 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020527850A Division JP2020528936A (ja) 2017-07-27 2018-07-26 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025011548A Division JP2025066140A (ja) 2017-07-27 2025-01-27 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2023089245A JP2023089245A (ja) 2023-06-27
JP2023089245A5 true JP2023089245A5 (https=) 2023-10-16
JP7629651B2 JP7629651B2 (ja) 2025-02-14

Family

ID=63165539

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020527850A Withdrawn JP2020528936A (ja) 2017-07-27 2018-07-26 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
JP2023069335A Active JP7629651B2 (ja) 2017-07-27 2023-04-20 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
JP2025011548A Pending JP2025066140A (ja) 2017-07-27 2025-01-27 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020527850A Withdrawn JP2020528936A (ja) 2017-07-27 2018-07-26 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025011548A Pending JP2025066140A (ja) 2017-07-27 2025-01-27 Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用

Country Status (8)

Country Link
US (3) US20210032364A1 (https=)
EP (1) EP3658178A1 (https=)
JP (3) JP2020528936A (https=)
CN (1) CN111491661B (https=)
AU (2) AU2018306436A1 (https=)
CA (1) CA3071105A1 (https=)
SG (1) SG11202000634UA (https=)
WO (1) WO2019023460A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098328A1 (en) * 2017-07-27 2022-03-31 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
SG11202000634UA (en) 2017-07-27 2020-02-27 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
CA3127776A1 (en) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
US20220153868A1 (en) * 2019-02-20 2022-05-19 Oncolyze, Inc Hdm2 antibody for use in treating cancer
CN116082500B (zh) * 2022-12-09 2023-08-22 珠海重链生物科技有限公司 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118497136A (zh) * 2024-06-06 2024-08-16 华中农业大学 一种高亲和力鼠抗乌鳢IgM单克隆抗体、杂交瘤细胞株及应用
GB202413802D0 (en) * 2024-09-19 2024-11-06 Univ Court Univ Of Glasgow MDM2 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE4345249C2 (de) 1993-11-19 1997-12-11 Deutsches Krebsforsch hdm-2-Fragmente mit Bindungsregionen für hdm-2-spezifische Antikörper
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
FR2738151B1 (fr) 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2224961A1 (en) 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US8822419B2 (en) 2008-10-03 2014-09-02 The Research Foundation Of State University Of New York Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
CN102274186B (zh) * 2010-06-11 2014-04-02 复旦大学 一种用于抗癌的镜像多肽脂质纳米制剂
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
SG11202000634UA (en) 2017-07-27 2020-02-27 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
CA3127776A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer

Similar Documents

Publication Publication Date Title
JP2023089245A5 (https=)
JP2020528936A5 (https=)
JP2020501531A5 (https=)
CN110799543A (zh) 肝细胞癌的免疫治疗
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2023037000A5 (https=)
US20210040213A1 (en) Immunomonotherapy for urothelial carcinoma
EP4486776A1 (en) Humanized antibodies against nectin-2 and drug conjugates thereof
JPWO2020081928A5 (https=)
JPWO2020185722A5 (https=)
IL321677A (en) Anti-PDL1 antibodies, multispecific antibodies, and methods of use
JPWO2021068841A5 (https=)
JPWO2023028653A5 (https=)
JPWO2019228514A5 (https=)
JPWO2020081497A5 (https=)
US20260014268A1 (en) Drug conjugates of humanized anti pvr antibodies
JPWO2020118295A5 (https=)
JPWO2023049999A5 (https=)
JPWO2022031710A5 (https=)
JPWO2023285552A5 (https=)
CA3066518C (en) Immunotherapy for hepatocellular carcinoma
RU2025100071A (ru) Антитела против siglec15 и их применения
JPWO2022263632A5 (https=)
RU2025127414A (ru) Антитела против 5т4 и их применения
RU2025128258A (ru) Анти-her3 и анти-met антитела и их применения